Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28452780 | 0.83 | MEN1 (0.33) | MAPTHPGD | |
| SCHEMBL17552126 | 0.75 | ESR2 (0.52) | ESR2MAPTNR1H2MAPK1 | |
| SCHEMBL17541088 | 0.71 | MEN1 (0.33) | MAPTHPGD | |
| SCHEMBL5467759 | 0.68 | KMT2A (0.64) | MAPTKDM4EPOLBTHRBALDH1A1 | |
| SCHEMBL30056523 | 0.67 | NOTUM (0.67) | ABHD6MAPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL464005 | 0.67 | NOTUM (0.67) | ABHD6MAPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL9693821 | 0.67 | HSP90AA1 (0.39) | PDGFRBMAPTALDH1A1HSD17B10MAPK1 | |
| SCHEMBL8108171 | 0.66 | ESR2 (0.53) | ABHD6ESR2NR1H2KDM4ETAS1R3 | |
| SCHEMBL7842940 | 0.65 | ABHD6 (0.64) | ABHD6ESR2MAPTNR1H2KDM4E | |
| SCHEMBL14185727 | 0.65 | NPC1 (0.32) | ABHD6PDGFRBMAPTTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812014-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| EP-1988093-A1 | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | Wyeth a Corporation of the State of Delaware (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1885357-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D BETA-LACTAMASES INHIBITORS | Wyeth (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006130588-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D BETA-LACTAMASES INHIBITORS | WYETH (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1499621-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASES INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
| WO-2003093279-A1 | BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, MGAM, PGLS | ABHD6 41/4885ESR2 1846/4885PDGFRB 1162/4885 |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, BPGM, B2M | ABHD6 239/4885ESR2 2080/4885PDGFRB 901/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | ABHD6 497/4885ESR2 2242/4885PDGFRB 1135/4885 |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, PEPD, B2M | ABHD6 226/4885ESR2 1290/4885PDGFRB 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.